Radiomics is a field of research in which image analysis is used to extract large number of quantitative features from medical images, such as MR, CT, and PET scans. While there are many potential applications of radiomics across the healthcare spectrum, oncology continues to be one of the main areas of study.

This paper looks at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them.

Austin, Texas-based Aeglea Biotherapeutics reported what initially appears to be positive outcomes for the company’s Phase III PEACE trial of pegzilarginase in Arginase 1 Deficiency (ARG1-D), a rare, progressive and debilitating disease marked by high levels of the amino acid arginine.

A late-stage trial of Biogen Inc.’s experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) failed to reach the study’s main goal, but secondary measures and biomarkers showed favorable trends, the company said on Oct. 17.

Artificial Intelligence (AI) is at the forefront of modern technology and has begun to parallel in the world of biotechnology. Many biopharma companies are using AI to drive innovation, enhance their processes and explore new business models.

BioSpace takes a look at some of the top stories from day one of the Annual Biomarkers for Alzheimer’s Disease Summit held August 25-26, 2021.

In a review of recently published scientific studies, investigators at Keck School of Medicine of USC identified a natural barrier to the inner’s sensory cells’ ability to regenerate.

The U.S. Food and Drug Administration made the decision to grant Breakthrough Therapy Designation to Mirati Therapeutics’ adagrasib for the potential treatment of non-small cell lung cancer (NSCLC) in patients harboring the KRASG12C mutation after systemic therapy.

Alzheimer’s disease is the holy grail of pharmaceutical research, and a team of physicians published results showing that they may have found the key to actually improving cognition in patients with early-stage dementia.

As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.